191 related articles for article (PubMed ID: 26094710)
1. Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.
Ursu R; Taillibert S; Banissi C; Vicaut E; Bailon O; Le Rhun E; Guillamo JS; Psimaras D; Tibi A; Sacko A; Marantidou A; Belin C; Carpentier AF
Cancer Sci; 2015 Sep; 106(9):1212-8. PubMed ID: 26094710
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
Ursu R; Carpentier A; Metellus P; Lubrano V; Laigle-Donadey F; Capelle L; Guyotat J; Langlois O; Bauchet L; Desseaux K; Tibi A; Chinot O; Lambert J; Carpentier AF
Eur J Cancer; 2017 Mar; 73():30-37. PubMed ID: 28142059
[TBL] [Abstract][Full Text] [Related]
3. CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
Otsuka T; Nishida S; Shibahara T; Temizoz B; Hamaguchi M; Shiroyama T; Kimura K; Miyake K; Hirata H; Mizuno Y; Yagita M; Manabe Y; Kuroda E; Takeda Y; Kida H; Ishii KJ; Kumanogoh A
BMC Cancer; 2022 Jul; 22(1):744. PubMed ID: 35799134
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
Carpentier A; Laigle-Donadey F; Zohar S; Capelle L; Behin A; Tibi A; Martin-Duverneuil N; Sanson M; Lacomblez L; Taillibert S; Puybasset L; Van Effenterre R; Delattre JY; Carpentier AF
Neuro Oncol; 2006 Jan; 8(1):60-6. PubMed ID: 16443949
[TBL] [Abstract][Full Text] [Related]
5. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
Link BK; Ballas ZK; Weisdorf D; Wooldridge JE; Bossler AD; Shannon M; Rasmussen WL; Krieg AM; Weiner GJ
J Immunother; 2006; 29(5):558-68. PubMed ID: 16971811
[TBL] [Abstract][Full Text] [Related]
6. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.
Carpentier A; Metellus P; Ursu R; Zohar S; Lafitte F; Barrié M; Meng Y; Richard M; Parizot C; Laigle-Donadey F; Gorochov G; Psimaras D; Sanson M; Tibi A; Chinot O; Carpentier AF
Neuro Oncol; 2010 Apr; 12(4):401-8. PubMed ID: 20308317
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.
Thompson JA; Kuzel T; Drucker BJ; Urba WJ; Bukowski RM
Clin Genitourin Cancer; 2009 Oct; 7(3):E58-65. PubMed ID: 19815483
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
[TBL] [Abstract][Full Text] [Related]
9. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Murad YM; Clay TM; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1257-66. PubMed ID: 17696823
[TBL] [Abstract][Full Text] [Related]
10. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
11. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
Wittig B; Schmidt M; Scheithauer W; Schmoll HJ
Crit Rev Oncol Hematol; 2015 Apr; 94(1):31-44. PubMed ID: 25577571
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.
Weihrauch MR; Richly H; von Bergwelt-Baildon MS; Becker HJ; Schmidt M; Hacker UT; Shimabukuro-Vornhagen A; Holtick U; Nokay B; Schroff M; Wittig B; Scheulen ME
Eur J Cancer; 2015 Jan; 51(2):146-56. PubMed ID: 25480557
[TBL] [Abstract][Full Text] [Related]
13. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
14. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
16. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
17. Successful combination of local CpG-ODN and radiotherapy in malignant glioma.
Meng Y; Carpentier AF; Chen L; Boisserie G; Simon JM; Mazeron JJ; Delattre JY
Int J Cancer; 2005 Oct; 116(6):992-7. PubMed ID: 15856470
[TBL] [Abstract][Full Text] [Related]
18. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
Behm B; Di Fazio P; Michl P; Neureiter D; Kemmerling R; Hahn EG; Strobel D; Gress T; Schuppan D; Wissniowski TT
Gut; 2016 Jan; 65(1):134-43. PubMed ID: 25524262
[TBL] [Abstract][Full Text] [Related]
19. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
McHutchison JG; Bacon BR; Gordon SC; Lawitz E; Shiffman M; Afdhal NH; Jacobson IM; Muir A; Al-Adhami M; Morris ML; Lekstrom-Himes JA; Efler SM; Davis HL
Hepatology; 2007 Nov; 46(5):1341-9. PubMed ID: 17929306
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
